Phase I study of CCW702, a bispecific small molecule-antibody conjugate targeting PSMA and CD3 in patients with metastatic castration-resistant prostate cancer (mCRPC).

Mark C. Markowski,Deepak Kilari,Mario A. Eisenberger,Rana R. McKay,Robert Dreicer,Mohit Trikha,Elisabeth I. Heath,Jing Li,Pamela D. Garzone,Travis S. Young

Phase I study of CCW702, a bispecific small molecule-antibody conjugate targeting PSMA and CD3 in patients with metastatic castration-resistant prostate cancer (mCRPC).

2021

Mark C. Markowski
Deepak Kilari
Mario A. Eisenberger
Rana R. McKay
Robert Dreicer
Mohit Trikha
Elisabeth I. Heath
Jing Li
Pamela D. Garzone
Travis S. Young

TPS5094Background: CCW702 is a novel bispecific antibody comprised of a small molecule imaging agent ligand (DUPA) with specificity for prostate specific membrane antigen (PSMA) conjugated to an an...

Keywords:

Imaging agent
Cancer research
CD3
Medicine
Small molecule
Conjugated system
Glutamate carboxypeptidase II
Prostate cancer
phase i study
Ligand (biochemistry)

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations